ArticleAnnals of translational medicine2024
Nationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.
Article in Annals of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD. Methods: We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD. Patients with myocardial infarction during index hospitalization, history of coronary artery bypass graft or renal transplantation and without Medicare AB coverage were excluded. Trends and related outcomes, including mortality and revascularization rate, were studied. Results: The mean age was 65.1 years with 57.5% male and a majority White (64.5%). The dialysis duration was ≤5 years in 83.3% patients. Hypertension (97.6%) and diabetes mellitus (76.8%) were the most common comorbidities. PCI procedures per 1,000 ESKD patients dropped from 6.2 in 2010 to 2.6 in 2018 (P<0.001) while the index hospitalization mortality increased from 0.9% to 3.0% (P<0.001). The 30-day and 1-year mortality also significantly increased from 3.2% to 6.1% and 26.5% to 31.9%, respectively. However, 1-year repeat revascularization rates dropped from 19.8% to 17.0% between 2010-2018 (P<0.001). A significant increase in comorbidity burden was also noted. Conclusions: We demonstrate a consistent decrease in PCI rates for SIHD in ESKD patients. However, the in-hospital mortality has increased significantly, in part, due to an increasing high-risk profile of these patients. Our results call for individualized clinical decision-making when exploring revascularization options in ESRD patients with SIHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.